The Board has elected Dr. Ajit Shetty, who had served as the Company's Interim Chairperson of the Board since December 9, 2023, as Chairperson of the Board, effective February 13, 2024
The restructuring aims to create synergies across the business and strengthen capital structure
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
The company recently received CEP certificate approval for Losartan Potassium by EDQM
The company will be preferred business partner for VPPL in terms of sourcing and supplying key raw materials
The registered capital of the newly founded company is € 50 million
An accomplished R&D leader and champion of the application of AI to drug discovery
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023
Subscribe To Our Newsletter & Stay Updated
